medigraphic.com

2019, Number 2

<< Back Next >>

Rev Hematol Mex 2019; 20 (2)

Treatment of FLT3-mutated acute myeloid leukemia (AML) with midostaurin in Mexico: the challenges in a developing country

Terreros-Muñoz E, Solís-Poblano JC, Reyes-Pérez EN, López-Marthen JL, Alvarado-Ibarra M, García-Stivalet LA, Limón-Flores A, Meillón-García L, Montaño-Figueroa EH, Zaragoza-Vázquez AN, Demichelis-Gómez R

Language: English
References: 23
Page: 117-123
PDF size: 275.44 Kb.


ABSTRACT

Background: The prognosis of acute myeloid leukemia (AML) is defined by cytogenetic and molecular assessment.
Objective: To analyze the data of eight centers of Mexico treating patients with acute myeloid leukemia with the standard treatment of their institution plus midostaurin.
Patients and Method: A retrospective study was done with all the patients with newly diagnosed AML in eight centers who were assessed for FLT3-ITD and TKD mutations from September 2016 to September 2017 and treated with midostaurin if they had any FLT3 mutation. We analyzed the data of eight centers in Mexico that treated AML patients with midostaurin and the standard treatment of their institution.
Results: We assessed FLT3 mutations in 79 patients with AML and found mutations in 11 (13.9%). We treated 7 AML-patients with chemotherapy and midostaurin: The CR rate was 100%. With a medium follow-up of 32.8 weeks, the overall survival and disease free survival were 71.4%. We reported adverse events associated with midostaurin in 57% of the total number of patients (4/7), all of them grade 1-2. In most cases the adverse effects were nausea and fatigue.
Conclusion: We have found, in concordance with previously reported data, that treatment with midostaurin is well tolerated and produces sustained responses. In developing countries we face for specific challenges for the diagnosis and treatment of AML.


REFERENCES

  1. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100(13):4325-36. doi: 10.1182/blood-2002-03-0772

  2. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116(3):354-65. doi: 10.1182/ blood-2009-11-254441

  3. Schlenk RF, Dohner KJ, Frohling S, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-18. doi: 10.1056/NEJMoa074306.

  4. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366(12):1079-89. doi: 10.1056/NEJMoa1112304

  5. Donher H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129(4):424- 47. doi: 10.1182/blood-2016-08-733196.

  6. Patel U, Luthra R, Medieros J, et al. Clin Lymphoma Myeloma Leuk 2017;17(S1):62-74. doi: 10.1016/j. clml.2017.02.015

  7. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002;100:4372-80. doi: 10.1182/blood-2002-05-1440

  8. Whitman SP, Maharry K, Radmacher MD, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010;116(18):3622-26. doi: 10.1182/ blood-2010-05-283648

  9. García JS, Stone RM. The development of FLT3 inhibitors in acute myeloid leukemia. Hematol Oncol Clin North Am 2017;31(4):663-80. doi: 10.1016/j.hoc.2017.03.002

  10. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017;377(5):454-464. doi: 10.1056/NEJMoa1614359

  11. Swerdlow SH, editor. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2017.

  12. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Myeloid Leukemia Version 3.2017- June 6, 2017.

  13. Gale RE, Green C, Allen C, et al; Medical Research Council Adult Leukaemia Working Party. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008;111(5):2776-2784. doi: 10.1182/ blood-2007-08-109090

  14. Pratcorona M, Brunet S, Nomdedeu J, et al; Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas. Favorable outcome of patients with acute myeloid leukemia harboring a low- allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood 2013;121(14):2734-2738. doi: 10.1182/blood-2012-06-431122

  15. Linch DC, Hills RK, Burnett AK, Khwaja A, Gale RE. Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate- risk acute myeloid leukemia. Blood 2014;124(2):273- 276. doi: 10.1182/blood-2014-02-554667

  16. Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006;107:3463-3468. doi: 10.1128/IAI.69.4.2487-2492.2001

  17. Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006;20:965-970. doi: 0.1038/sj.leu.2404188

  18. Park SH, Chi HS, Min SK, et al. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res 2011;35:1376-1383. doi: 10.1016/j. leukres.2011.06.003

  19. Jones D, Yao H, Romans A, et al. Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias. Genes Chromosomes Cancer 2010;49(2):182-191. doi: 10.1002/gcc.20732

  20. Mead AJ, Linch DC, Hills RK, et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007;110(4):1262-1270. doi: 10.1182/ blood-2006-04-015826

  21. Paschka P, Du J, Schlenk RF, et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood 2013;121(1):170-177. doi: 10.1182/ blood-2012-05-431486

  22. Borthakur G, Cortés JE, Estery EE, et al. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol 2014 Oct;89(10):964-968. doi: 10.1002/ajh.23795

  23. Registro Histopatológico de Neoplasias en México. Dirección General de Epidemiología, Secretaría de Salud. http://www.eluniversal.com.mx/articulo/cartera/economia/ 2016/11/30/en-mexico-solo-el-88-cuenta-con-segurode- gastos-medicos. 1998




2020     |     www.medigraphic.com